Accreditation Information

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join leading expert Dr. Cody Stanford for this clinical snapshot, providing practical insights and multidisciplinary perspectives essential for bridging the gap between global clinical evidence and localized patient care in daily practice.

This activity is intended for:

This activity is intended for primary care providers who care for patients with obesity.

Faculty involved in this program:

Fatima Cody Stanford, MD, MPH, MPA, MBA, MACP, FAAP, FAHA, FAMWA, FTOS is an internationally recognized obesity medicine physician-scientist, educator, and policymaker at Massachusetts General Hospital and Harvard Medical School. Dr. Stanford provides comprehensive, evidence-based care to patients while leading national efforts to eliminate weight stigma and reshape the understanding of obesity as a chronic disease.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Fatima Cody Stanford, faculty for this educational activity, has the following relevant financial relationships:
Consultant/Principal Investigator for Eli Lilly
Consultant, advisor, or speaker for Novo Nordisk, Amgen, Boehringer Ingelheim, AstraZeneca, AbbVie, Currax, Clearmind Medicine

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008073-9999-26-199-H01-P)
Type of Activity: Knowledge
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until May 29th 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit
Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from June 17th 2026 through May 29th 2027.

1. Review the objectives and disclosures
2. Study the educational content
3. Successfully complete activity post-test(s)
4. Complete the activity evaluation

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.
This continuing education activity is active starting June 17th 2026, and will expire on May 29th 2027.
Estimated time to complete this activity: 15 minutes.

Learning objective
Upon completion of this activity, participants should be able to:

• Assess the efficacy of induction therapies to formulate advancing treatment plans that include appropriate maintenance options and prevent relapse.